Could be only ONE employee at Omeros?? All that "concentration of power", as you say, seems incongruent with basic corporate governance and the more risk-focused Sarbanes rules and regs...but not my area of expertise. Any lawyers out there who can weigh in?
MISSING in these recent conversations is that this IPO is a real biotech company with real products going thru Phase 2 and 3 trials, a real pipeline of novel drugs working thru pre-clinical trials, and a real IP which includes 65 GPCRs (novel receptors in the body) which they're looking to de-orphanize, auction off to other companies and develop themselves in the future.
The company's prospectus estimateds that the sales for orthopedic joint irrigation product alone could exceed $1 billion annually with extremely high margins. Additionally, the value of Omeros' GPCR targets, as evidenced by Novartis’s $200 million recent licensure/partnership deals with Heptares-Ascent, could bring in multiples of this as the auctions off newly de-orphanized GPCRs to other pharma companies.
I think it's easy for peoples eyes to glaze over when discussing the technical side of biotechnology -- it's certainly more fun to trash and throw accusations around about a declining IPO -- but there's some good reasons the underwriters wanted to take this company public and once the quiet period is over on the 8th we may hear many more details about the future course of this company.
Gaudisso - you sure are a knowledgeable source of the OMER story (refer to "joint irrigation" product and what is basis for stating there will be "extremely high margins"?) and also of legal IPO requirements (how many folks know about the "quiet period" and what does this really mean anyway?). What are your sources? Insider? If credible, the info could be helpful.
Outstanding post, Guadisso. I hope when the quiet period is over that Omeros makes the pre-IPO video or an equivalent video available. I've been happily buying OMER in this post-IPO SP "canyon". OMER has a terrific pipeline of both drugs and processes.